One of the Good Companies

We create a future for medical cannabis throughout Europe
Farmako GmbH is a research-based pharmaceutical company. Traditional research on pharmaceutical products has produced countless revolutions in the past century that have improved the lives of billions of people. Since the 1920s, however, research and development of pharmaceutical products based on the cannabis plant has been massively restricted or banned. We have set ourselves on helping to catch up on this research backlog of almost 100 years for cannabis based pharmaceuticals.

The Farmako is ready to drive this transformation worldwide.

Our Mission
The European Market

Europe will be the largest cannabis market in the world, by the year 2028. Known for its considered and conservative approach to change, Europe is suddenly becoming a hotbed of activity for the global cannabis industry. Home to a population of over 742 million, more than double the US and Canada combined, Europe is a global economic powerhouse with an annual GDP of over €15t in 2017 and a total annual healthcare spend of €2.3t.
German Market

The German market for medical cannabis is estimated at 19.1 million euros in 2018. By 2019, the market in Germany is expected to grow to around 200 million euros. For 2028, experts expect a market volume for medical cannabis of 7.8 billion euros in Germany, an increase by a factor of 400.
It is estimated that there are as many as 3.6 million active cannabis users in the UK, contributing to an estimated black market value of up to €6b per year. In addition, according to research medical cannabis can treat up to 2.9 million patients in the UK.
Farmako plans to become a vertically integrated leader in every European country with a legal basis in this market. Farmako already has branches in Germany and the United Kingdom. The company relies on medical cannabis and focuses on research to develop new pharmaceutical products such as capsules, oils or inhalers.
We are a research based pharmaceutical company. On January 9th, we will publish the first of many patents to come. And this is just the beginning. Our research and development will continue to disclose upcoming patents in January and February in the upcoming year.

R&D makes the difference

More stable supply in quality, quantity and composition of medical cannabis

- Alternative Generation of Cannabinoids and Terpenes via Cannasis™
- New production processes of creating pharmaceutical products

- New and individualised pharmaceutical products like capsules, inhalers, liquids, lotion, drops with varying levels of CBD and THC
- Medical trials with patients and doctors
- Research in better (and more individual) application of medical cannabis for known conditions
- Application of medical cannabis to new areas of therapeutic use on varying conditions
- Development of recreational products for specific needs
NIKLAS KOUPARANIS
Niklas Kouparanis was the second employee and authorized officer of one of the currently leading German companies for medical cannabis. He shaped the industry as an established expert in the field, consultant to European governments, and supervisor to one of the first German-Canadian market entrances.

SEBASTIAN DIEMER
Sebastian is often described as one of Germany’s most successful founders. He has already successfully set up five companies, creating more than 1,000 jobs and raising over €300 million in venture capital. His companies always pursued a global focus. He is founder and shareholder.

PATRICK SCHMITT
Patrick Schmitt is molecular biologist, state-approved pharmaceutical consultant and certified expert for medicine, drugs and nutritional supplements. He has several years of experience in product development and advising pharmaceutical companies and authorities on regulatory issues. He is also one of the most sought after experts for development, patent registration, licensing and evaluation of functional foods and drugs. His work has already found expression in over 500 products on the market and a large number of registered patents. At Farmako, he leads research and development. He is founder and shareholder.

MARCUS EWALD
Marcus is the managing partner of Ewald & Rössing, a crisis management consultancy. He is the federal chairman of the Young Economic Council of Germany, founded the Federal Blockchain Association and the Federal Association of AI. At Farmako, he directs public relations and public affairs. He is founder and shareholder.

TORSTEN RÖSSING
Torsten is the managing partner of Ewald & Rössing, a crisis management consultancy. He is the regional chairman of the German Public Relations Association in Hesse, Rhineland-Palatinate and Saarland. At Farmako, he manages regulation and privacy. He is founder and shareholder.

MARIO REICHENBACH
Mario was one of the first employees of one of the first and largest companies in the German cannabis market. He has successfully established an exemplary business development there and is one of the experts in the industry.
Global Presence

We’re already present in multiple countries in Europe with plans to have offices in every country of European Union by 2020.
With Canada and California, two huge markets have already revolutionized their healthcare. The German market alone is almost as big as these two together. Together, European markets will become the global powerhouse of medical cannabis.

*And Farmako will lead that revolution in Europe.*